HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Joanna C Neill Selected Research

Phencyclidine (Angel Dust)

1/2022The comparative effects of mGlu5 receptor positive allosteric modulators VU0409551 and VU0360172 on cognitive deficits and signalling in the sub-chronic PCP rat model for schizophrenia.
10/2019Global brain volume reductions in a sub-chronic phencyclidine animal model for schizophrenia and their relationship to recognition memory.
11/2018NMDA receptor antagonist rodent models for cognition in schizophrenia and identification of novel drug treatments, an update.
1/2017Dopamine dysregulation in the prefrontal cortex relates to cognitive deficits in the sub-chronic PCP-model for schizophrenia: A preliminary investigation.
11/2016Modelling the cognitive and neuropathological features of schizophrenia with phencyclidine.
10/2016Towards the development of improved tests for negative symptoms of schizophrenia in a validated animal model.
3/2011Phencyclidine (PCP)-induced disruption in cognitive performance is gender-specific and associated with a reduction in brain-derived neurotrophic factor (BDNF) in specific regions of the female rat brain.
12/2010Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism.
9/2010Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.
10/2009Role of 5-HT receptor mechanisms in sub-chronic PCP-induced reversal learning deficits in the rat.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Joanna C Neill Research Topics

Disease

24Schizophrenia (Dementia Praecox)
01/2022 - 03/2002
8Cognitive Dysfunction
01/2022 - 09/2010
4Weight Gain
11/2009 - 03/2002
2Psychotic Disorders (Schizoaffective Disorder)
01/2021 - 01/2016
2Body Weight (Weight, Body)
01/2019 - 11/2009
2Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
04/2015 - 08/2014
1Autistic Disorder (Autism)
01/2022
1Substance Withdrawal Syndrome (Withdrawal Symptoms)
09/2021
1Treatment-Resistant Schizophrenia
01/2021
1Memory Disorders (Memory Loss)
01/2018
1Traumatic Brain Injuries (Traumatic Brain Injury)
05/2015
1Neoplasms (Cancer)
05/2015
1Alzheimer Disease (Alzheimer's Disease)
09/2010

Drug/Important Bio-Agent (IBA)

13Phencyclidine (Angel Dust)IBA
01/2022 - 03/2008
8Antipsychotic Agents (Antipsychotics)IBA
01/2022 - 03/2002
4N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA
11/2018 - 05/2008
3Pharmaceutical PreparationsIBA
10/2021 - 11/2009
3Olanzapine (Zyprexa)FDA Link
11/2009 - 03/2002
2Interleukin-6 (Interleukin 6)IBA
01/2022 - 01/2019
2Dizocilpine Maleate (Dizocilpine)IBA
11/2018 - 12/2010
2KetamineFDA LinkGeneric
11/2018 - 12/2010
2Dopamine (Intropin)FDA LinkGeneric
01/2017 - 04/2015
2gamma-Aminobutyric Acid (GABA)IBA
11/2016 - 01/2004
2Neurotransmitter Agents (Neurotransmitter)IBA
11/2016 - 01/2004
2Calcium-Binding ProteinsIBA
11/2016 - 01/2004
2ParvalbuminsIBA
11/2016 - 01/2016
2Clozapine (Clozaril)FDA LinkGeneric
11/2009 - 03/2002
1VU0409551IBA
01/2022
1N- cyclobutyl- 6- ((3- fluorophenyl)ethynyl)nicotinamideIBA
01/2022
1Biological ProductsIBA
10/2021
1Antidepressive Agents (Antidepressants)IBA
09/2021
1SEP-363856IBA
04/2021
1PyridoxamineIBA
10/2019
1Amyloid (Amyloid Fibrils)IBA
01/2018
1TransferasesIBA
04/2015
12-(3',4',5',6'-tetrahydro-2'H-(2,4') bipyridinyl-1'-yl)-N-m-tolyl-acetamideIBA
04/2015
1catechol (pyrocatechol)IBA
04/2015
1Dopamine D4 Receptors (Dopamine D4 Receptor)IBA
04/2015
1Tolcapone (Tasmar)FDA Link
04/2015
1N- ((4- (2- cyanophenyl)- 1- piperazinyl)methyl)- 3- methylbenzamideIBA
06/2011
1Brain-Derived Neurotrophic Factor (BDNF)IBA
03/2011
1Nerve Growth Factors (Neurotrophins)IBA
03/2011
1N-Methylaspartate (NMDA)IBA
12/2010
18- (4- methylpiperazin- 1- yl)- 3- phenylsulfonylquinolineIBA
09/2010
1(2- (6- fluoro- 1H- indol- 3- yl)- ethyl)- (3- (2,2,3,3- tetrafluoropropoxy)benzyl)amineIBA
09/2010
1Histamine H1 AntagonistsIBA
11/2009
1Haloperidol (Haldol)FDA LinkGeneric
11/2009
1Pyrilamine (Mepyramine)FDA Link
11/2009
1Histamine H1 Receptors (Histamine H1 Receptor)IBA
11/2009
1SB 243213IBA
11/2009
15-HT2C Serotonin ReceptorIBA
11/2009
1Serotonin 5-HT2 Receptor AntagonistsIBA
11/2009
1Serotonin ReceptorsIBA
10/2009
1Aripiprazole (Abilify)FDA Link
08/2008
1Fluoxetine (Prozac)FDA LinkGeneric
08/2008
1ziprasidone (Geodon)FDA Link
11/2004
1Calbindin 2IBA
01/2004
1CalbindinsIBA
01/2004

Therapy/Procedure

3Drug Therapy (Chemotherapy)
05/2015 - 09/2010
2Therapeutics
10/2019 - 12/2010
1Drug Tapering
01/2021
1Secondary Prevention
01/2021
1Injections
11/2009